WO2019088311A1 - Stat3 저해활성을 갖는 화합물 및 이의 용도 - Google Patents
Stat3 저해활성을 갖는 화합물 및 이의 용도 Download PDFInfo
- Publication number
- WO2019088311A1 WO2019088311A1 PCT/KR2017/012151 KR2017012151W WO2019088311A1 WO 2019088311 A1 WO2019088311 A1 WO 2019088311A1 KR 2017012151 W KR2017012151 W KR 2017012151W WO 2019088311 A1 WO2019088311 A1 WO 2019088311A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- cancer
- disease
- stat3
- autoimmune
- Prior art date
Links
- 0 CC(CCN)=Nc(cccc1)c1C(N=*)=* Chemical compound CC(CCN)=Nc(cccc1)c1C(N=*)=* 0.000 description 5
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
- C07D279/06—1,3-Thiazines; Hydrogenated 1,3-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to a compound having STAT3 inhibitory activity, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and pharmaceutical use thereof.
- STAT3 signal transducer and activator of transcription 3
- HIF-1alpha hypoxia inducible factor-1alpha
- caffeic acid derivatives effectively inhibited the expression of VEGF gene by inhibiting the activity of tyrosine-705 of STAT3 (Jung JE, et al . Carcinogenesis . 28, 1780-1787 (2007)).
- STATs are transcription factors that are activated by phosphorylation by JAK (Januse Kinase), EGFR (Platelet-derived Growth Factor Receptor), and PDGFR (Darnell JE Jr Science, 277, 1630-1635 (1997)). It is known that STATs activated by phosphorylation induce transcription of various genes associated with the disease by forming a dimer and moving into the nucleus and binding to the promoter of the target gene (Darnell JE Jr. Science 277, Bromberg JF, et al . Cell . 98, 295-303 (1999)).
- STAT3 is known to be overactivated in a wide variety of human tumors including blood and solid tumors (Bromberg JF, et al . Cell . 98, 295-303 (1999)
- Activated STAT3 is known to promote the cancer cell transformation of mutated cells by promoting the expression of target genes such as Bcl-XL, c-myc, and cyclin D1 associated with the survival, proliferation and growth of cancer cells (Vera J, et al . Prog Biophys Mol Biol . 106, 426-434 (2011); Turkson J. Expert Opin Ther Targets . 8, 409-422 (2004)).
- the present inventors have sought to develop new compounds having selective inhibitory activity against STAT3 for the prevention and treatment of diseases associated with overexpression or activation of STAT3 such as cancer, autoimmune diseases and inflammatory diseases.
- diseases associated with overexpression or activation of STAT3 such as cancer, autoimmune diseases and inflammatory diseases.
- derivatives having 3-phenoxymethyl-1,2,4-oxadiazole or 3-phenoxymethyl-1,2,4-thiadiazole skeleton inhibit activation of STAT3, .
- caspase-3 and PARP were activated, the activity of MMPs was inhibited, and the expression of Twist gene was effectively inhibited, thereby being effective for diseases caused by STAT3.
- an object of the present invention is to provide a compound of the following general formulas (1) to (60), or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- a compound selected from the group consisting of compounds represented by the following formulas (1) to (60), or a pharmaceutically acceptable salt, solvate or hydrate thereof:
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising (a) a pharmaceutically effective amount of a compound selected from the group consisting of the compounds represented by the above Chemical Formulas 1 to 60, or a pharmaceutically acceptable salt, solvate or hydrate thereof; And (b) a pharmaceutically acceptable carrier.
- the present invention also provides a pharmaceutical composition for preventing or treating a STAT3-related disease.
- prophylactic means any action that inhibits or slows progression of STAT3-related disease by administration of a composition of the present invention and the term & ii) relieving the disease and (iii) removing the disease.
- the cancer is selected from the group consisting of gastric cancer, colorectal cancer, lung cancer, breast cancer, ovarian cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, colon cancer, cervical cancer, Skin cancer, thyroid cancer, leukemia, lymphoma, adrenocortical cancer, pituitary cancer, ureteral cancer, glioma, esophageal cancer, small bowel cancer, glioblastoma, brain tumor and kidney cancer.
- the autoimmune disease is selected from the group consisting of alopecia greata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune adison disease, autoimmune disease of adrenal gland, autoimmune hemolytic anemia, Autoimmune thrombocytopenia, autoimmune thrombocytopenia, autoimmune thrombocytopenia, pemphigus vulgaris, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue syndrome, chronic inflammatory dehydration, multiple neuropathy
- the present invention also relates to a method of treating a condition selected from the group consisting of Churg-strauss syndrome, anti-inflammatory pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, disc lupus, abdominal complex cold globulinemia, fibromyalgia- Reinvale syndrome, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopen
- the compounds represented by formulas (1) to (60) of the present invention selectively inhibit the activity of STAT3 and inhibit the metastasis of cancer cells.
- the compounds of the present invention effectively inhibit the activation of caspase-3 and PARP, the inhibition of the activity of MMPs, and the expression of the Twist gene, thus effectively suppressing the growth and metastasis of human tumor cells .
- the pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration or the like.
- the appropriate dosage of the pharmaceutical composition of the present invention may vary depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate, .
- the daily dose of the pharmaceutical composition of the present invention is, for example, 0.0001-100 mg / kg.
- the food composition of the present invention includes components that are ordinarily added during the manufacture of food, and includes, for example, proteins, carbohydrates, fats, nutrients, flavoring agents, and flavoring agents.
- examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol.
- Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings.
- tau martin and stevia extract e.g., rebaudioside A and glycyrrhizin
- synthetic flavorings sacharine, aspartame, etc.
- the food composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), dietary components, synthetic flavors and natural flavors, colorants and heavies (cheese, Salts of alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like.
- a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), dietary components, synthetic flavors and natural flavors, colorants and heavies (cheese, Salts of alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like.
- citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, various plant extracts and the like
- the present invention provides a cosmetic composition (functional cosmetic composition) for preventing or ameliorating a STAT3-related disease comprising a compound selected from the group consisting of the compounds represented by the formulas (1) to (60) or a salt thereof as an active ingredient do.
- the present invention provides the use of a compound selected from the group consisting of the compounds represented by the above Chemical Formulas (1) to (60) or a salt thereof for use as a cosmetic composition (functional cosmetic composition) for preventing or ameliorating a disease associated with STAT3.
- the present invention provides novel compounds having STAT3 inhibitory activity and uses thereof.
- a pharmaceutical, functional cosmetic, a cosmetic, a functional food (neutraceutical) or a food composition can be prepared using the compound of the present invention as an active ingredient.
- the compound of the present invention effectively inhibits the abnormal activity of STAT3 associated with various diseases, and thus can be usefully used for prevention and treatment of various STAT3-related diseases related to cancer, autoimmune diseases, inflammatory diseases and the like.
- 1A to 1G show a model using a binding-molecular structure model for the SH2 domain in which Drosophila and human-derived cancer cells and STAT3 bind, showing that the ODZ17690 compound of the present invention has selective activity against STAT3.
- FIGS. 4A to 4H show the binding-molecular structure model of the ODZ10117 compound to the SH2 domain to which STAT3 binds and the action of STAT3 in various human cancer cells.
- FIGS. 5A to 5C show that ODZ10117 compounds inhibited the activity of STAT3 in human-derived glioblastoma (U87-MG) cells and breast cancer cells (MDA-MB-231).
- FIGS. 6A and 6B show that ODZ10117 compound inhibited the activity of STAT92E (STAT of mammals) in Drosophila cells.
- Figures 7A-7D show that ODZ10117 compounds inhibited the activity of STAT3 in various types of human glioblastoma.
- Figures 8A-8C show that ODZ10117 inhibited the activity of STAT3 in various types of breast cancer cells.
- 11A to 11E show that the compound ODZ10117 inhibited the proliferation of U87-MG cells and MDA-MB-231 cells and induced apoptosis.
- Figures 12A-12D show that the ODZ10117 compound inhibited the migration and infiltration of U87-MG and MDA-MB-231 cells.
- FIGS. 14A to 14D show STAT3 inhibitory activities of the 46 compounds shown in [Table 1] of the present invention in human hodgkin's lymphoma cell line.
- 15A and 15B show the STAT3 inhibitory activity of 33 compounds in which the activity of inhibiting STAT3 was shown to be superior among the 44 kinds of compounds shown in Table 1 of the present invention in the human hodgkin's lymphoma cell line.
- Fig. 16 shows the STAT3 inhibitory activity of the two compounds in which the STAT3-inhibiting activity was most excellent among the 44 compounds shown in Table 1 of the present invention.
- Triethylamine (2.70 ml, 19.52 mmol) was dissolved in a 50% aqueous ethanol solution (21 ml) and then hydroxylamine hydrochloride (1.36 g, 19.52 mmol) was added at room temperature. After stirring at room temperature for 5 minutes, the obtained 2- (2,4-dichlorophenoxy) acetonitrile was dissolved in ethanol (83 ml), and the mixture was refluxed at 100 ° C for 3 hours. Thereafter, the reaction mixture was diluted with water, filtered, and again washed with water to obtain the desired compound (2.71 g, 77%).
- the X 24 3 cells were S2-NP cell and reporter construct expression tree is established at a predetermined ratio in the presence of the compound, and the expression level of STAT92E And the inhibition effect was compared with the group treated with DMSO. In addition, the inhibitory effect was compared with that of AG490, nifuroxazide, NSC628869 (STA-21 or STA) or NSC74859 (S31-001) treated group as a positive control group.
- the human cancer cell lines used in the experiments are U87-MG (human glioblastoma) and MDA-MB-231 (human breast cancer) cell lines, and various kinds of human-derived blood cancer and solid cancer cells And cultured as described (Jung JE, et al . FASEB J. 19, 1296-1298 (2005)).
- the human Hodgkin's lymphoma cell lines L540 and HLDM-2 used in the experiments were obtained from a German Collection of Microorganisms and Cell Cultures (DSMZ, Germany) and cultured in RPMI 1640 medium containing 20% FBS at 5% CO 2 incubator.
- the three-dimensional structure of the portion corresponding to the SH2 domain was used in the X-ray crystal structure of STAT3 (PDB ID: 1BG1) (Becker S, et al . Nature 394, 145-151 (1998) Ver. 11) was used to calculate the minimum energy (Case DA, et al . J Comput Chem . 26, 1668-1688 (2005)).
- PDB ID: 1BG1 X-ray crystal structure of STAT3
- 500 structures were generated for all compounds, including ODZ10117, and molecular dynamics simulation was performed.
- the reporter construct plasmid DNA having STAT3-TA-luciferase
- the reporter construct was transiently expressed in HEK293T cells using Lipofectamine 2000, treated with ODZ10117, and the level of STAT3 expression was measured with a luminescence meter and compared with the DMSO treatment group The inhibitory effect was compared. In addition, the inhibitory effect was compared with that of AG490, nifuroxazide, NSC628869 (STA-21 or STA) or NSC74859 (S31-001) treated group as a positive control group.
- RNA isolation and real-time PCR were performed as previously described (Jung JE, et al . FASEB J. 19, 1296-1298 (2005)).
- Primer specific primers for human-derived Bcl-XL, Bcl-2, Twist, and GADPH genes were mixed with QuantiFast SYBR Green PCR master mix and amplified using Applied Biosystems 7300 real-time PCR system.
- the growth factor reduced matrigel was diluted 1: 3 in serum-free culture medium, transferred to a 24-well plate, and solidified at 37 ° C for 5 hours.
- Cells were added to the solidified matrigel by adding 1% serum-added culture, followed by adding 600 ⁇ l of a culture solution containing 10% serum containing 5 ⁇ l / ml of fibronectin and culturing for 24 hours.
- the cells were fixed and stained with Diffquick solution, and then observed with a Leica Application Suite microscope and images were taken.
- each cell was washed with FACS buffer and centrifuged at 2000 rpm for 2 minutes.
- the washed cells were stained with propidium iodide for 15 minutes, analyzed by FACS Canto flow cytometry, and analyzed by Flow-Jo software.
- the degree of inhibition of human tumor cell formation was determined by directly injecting 40 [mu] M ODZ10117 into human tumor on day 0, day 3, and day 5 from the 4th week of tumor cell injection. On day 7, the tumor was sacrificed, The tumor cell inhibitory effect of the drug was measured in comparison with the control group treated with DMSO.
- Tumors isolated from rats were fixed with formalin, embedded in paraffin, and sectioned from each paraffin block. The sections were stained with hematoxylin-eosin, phospho-STAT3, cleaved caspase-3, Bcl-XL, Ki67, and pro / active MMP-2 for histological evaluation.
- the paraffin was removed from the slice, the water was removed using alcohol, and the mixture was heated in 10 mM sodium hydroxide buffer (pH 6.0) for 5 minutes using a microwave.
- ODZ17690 expresses STAT 92E activated by the activity of Hop (corresponding to the mammalian JAK), which is a higher level of the ligand upd or STAT92E (corresponding to the STAT of the mammal) (Fig. 1B and Fig. 1B). Also in the human cancer cell L540 cells, ODZ17690 effectively inhibited the phosphorylation of STAT3's tyrosine residue 705 and the expression of SOCS3, a subordinate regulator (Fig. 1d).
- ODZ17690 selectively inhibited the phosphorylation of STAT3's tyrosine residue 705 (FIG. 1e).
- the pTyr-Leu substrate of the STAT3 selective inhibitors NSC-628869 and NSC-74859 which are known as standard substances in the binding-molecule model for the SH2 domain as the binding site of STAT3, selectively inhibits the SH2 domain, (Fig. 1F).
- ODZ17690 also binds well to the SH2 domain and has the lowest binding energy, similar to the control (Fig. 1g).
- a compound having a skeleton of 3-phenoxymethyl-1,2,4-oxadiazole or 3-phenoxymethyl-1,2,4- Lysophosphatidylcholine and STAT3-luciferase constructs in Drosophila cells and selectively express STAT3 were performed in human breast cancer cell-derived MDA-MB-231 cells.
- Figs. 3A and 3B thirteen compounds judged to have excellent efficacy were selected as final candidates.
- Western blot analysis was performed using thirteen kinds of compounds to confirm the compounds that were judged to be superior in STAT3 inhibitory activity. Among them, ODZ10117 was judged to be the most excellent (FIG. 3C).
- the selective STAT3 inhibitory effect of compound ODZ10117 was confirmed by a structure-binding molecule model.
- a structure-binding molecule model When modeling the binding of phosphorylated tyrosine residues to the SH2 domain, it was found that ODZ10117 binds appropriately (cyan).
- the binding to the SH2 domain was similar to that of NSC628869 (yellow) and NSC74859 (pink), which are known as selective STAT3 inhibitors.
- ODG10117, NSC628869 and NSC74859 were also found to be -11.14 kcal / mol, -10.89 kcal / 10.01 kcal / mol, indicating that the binding ability is superior to that of the control substance (Figs. 4A and 4C are ODZ10117).
- the binding of the Pro-pTyr-Leu to the SH2 domain in the X-ray complex complex was indicated in green ( Figures 4a and 4b).
- ODZ10117 showed better STAT3 inhibitory potency than NSC628869 and NSC74859, which are known as selective STAT3 inhibitors (Fig. 7d).
- STAT3 dimerization The inhibition of the STAT3 dimerization, nuclear translocation and transcriptional activity of the compound ODZ10117 was confirmed.
- STAT3-Flag DNA construct or STAT3-HA DNA construct was transformed into HEK293T cell line and subjected to immunoprecipitation and Western blot analysis.
- ODZ10117 inhibited the STAT3 dimerization reaction (Fig. 8A).
- ODZ10117 was superior to napamycansin in inhibiting the STAT3 dimerization reaction (Fig. 9B). Then, to confirm nuclear migration of STAT3, nuclear migration of STAT3 was observed by fluorescence microscopy using the cell line.
- Activated STAT3 in cancer cells increases the expression and proliferation of cells associated with cell survival. Therefore, when cell viability was examined after treating ODZ10117 at various concentrations in human glioblastoma treated with IL-6 for 24 hours or 48 hours, ODZ10117-treated group showed cell survival in a concentration-dependent manner (Fig. 10).
- Activated STAT3 in cancer cells increases cell proliferation and growth by increasing the expression of proteins related to cell survival and cell cycle. Therefore, when the effect of ODZ10117 upon cell proliferation of U87-MG and MDA-MB-231 cell lines was checked by time, ODZ10117 effectively inhibited the proliferation of both cells as compared with the control group treated with DMSO (Fig. 11A) .
- DMSO DMSO
- compounds were treated for 48 hours, stained with PI (propidium iodide) and Annexin V, and flow cytometry was performed.
- ODZ10117 induced apoptosis of about 15.3-26.7% and 40.2-43.0% for U87-MG and MDA-MB-231 cell lines, respectively (FIGS. 11b and 11c). Since the expression of various genes is involved in apoptosis, the activity of caspase-3 and PARP, which are typical pro-apoptosis genes involved in apoptosis, are analyzed by Western blot analysis. ODZ10117 showed a marked increase in the amount of fragmented caspase-3 and PARP protein, indicating that the activity of these proteins was increased. As a result, it was confirmed that ODZ10117 induces apoptosis by increasing the activity of caspase-3 and PARP (FIG. 11D).
- ODZ10117 effectively suppressed the expression of these genes (Fig. 11E). From the above results, it was confirmed that ODZ10117 increases the activity of pro-apoptosis gene and decreases the expression of anti-apoptosis gene, thereby increasing the apoptosis of cancer cells.
- ODZ10117 The efficacy of ODZ10117 on cell migration and invasiveness associated with metastasis of human tumor cells was confirmed.
- wound healing assay was performed to confirm the effect on cell mobility.
- the compounds were treated with U87-MG and MDA-MB-231 cells for 24 hours and the cell migration was confirmed by microscopy, the control group treated with DMSO showed cell migration vigorously, but ODZ10117 significantly inhibited the migration of these cells (Fig. 12A).
- ODZ10117 significantly inhibited tumor growth compared with the control group injected with DMSO (Fig. 13A and Fig. 13B).
- mice On the seventh day after drug administration, the mice were anesthetized and sacrificed to remove tumor masses.
- the expression of phosphorylation, Ki67, caspase-3 and Bcl-XL and pro / activated MMP2 of STAT3 tyrosine 705 residues were analyzed in tissue sections fixed with formalin and embedded in paraffin.
- the phosphorylation of STAT3 was markedly decreased as compared with the control group injected with DMSO.
- Ki67 one of the cell growth factors, Bcl-XL associated with apoptosis resistance, and pro / active MMP2 associated with cell invasion were significantly reduced.
- caspase-3 activity associated with apoptosis Figure 13c).
- DMSO or ODZ10117 was directly injected into rats injected with the human cancer cell line U87-MG cells, and survival rate was confirmed. As a result, the survival time of ODZ10117 was increased as compared with the control group injected with DMSO (Fig. 13D).
- ODZ10117 selectively inhibits the activity of STAT3, inhibiting growth and proliferation, invasion and metastasis of tumor cells, inducing the death of cancer cells, and inhibiting tumor growth.
- the present invention relates to a compound having STAT3 inhibitory activity, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a pharmaceutical use thereof, wherein the compound having STAT3 inhibitory activity of the present invention or a pharmaceutically acceptable salt thereof Possible salts, solvates or hydrates may be useful for the prevention and treatment of various STAT3 related diseases related to cancer, autoimmune diseases, inflammatory diseases, and the like.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
No. | ID | 분자량 | Mol Name |
1 | 4009697 | 280.2 | 2-(2-aminoethyl)-4(3H)-quinazolinone dihydrochloride hydrate |
2 | 7952466 | 453.9 | 2-chloro-5-{5-[(2-{[(4-methylphenyl)sulfonyl]amino}ethyl)thio]-1H-tetrazol-1-yl}benzoic acid |
3 | 5118596 | 293.3 | 1-(3-pyridinyl)-2,3,4,9-tetrahydro-1H-beta-carboline-3-carboxylic acid |
4 | 9034114 | 301.4 | N-[2-(1H-benzimidazol-2-yl)ethyl]benzenesulfonamide |
5 | 5277898 | 207.2 | 5-(2-hydroxybenzylidene)-1,3-thiazolidin-4-one |
6 | 9003625 | 287.3 | N-(1H-benzimidazol-2-ylmethyl)benzenesulfonamide |
7 | 9199753 | 282.3 | N-(methylsulfonyl)tryptophan |
8 | 5131328 | 308.3 | 1-(4-hydroxyphenyl)-2,3,4,9-tetrahydro-1H-beta-carboline-3-carboxylic acid |
9 | 5154969 | 431.9 | 2-chloro-N-({[4-hydroxy-6-(2-phenylvinyl)-1,3,5-triazin-2-yl]amino}carbonyl)benzenesulfonamide |
10 | 7815802 | 342.8 | N~4~-(3-chlorophenyl)-N~2~-(3-isopropoxypropyl)asparagine |
11 | 7579859 | 345.3 | 3-({[3-(trifluoromethyl)phenyl]sulfonyl}amino)benzoic acid |
12 | 5107319 | 283.3 | 3-(2-aminoethyl)-5-(aminosulfonyl)-1H-indole-2-carboxylic acid |
13 | 9235510 | 297.4 | N-[5-(4-pyridinylmethyl)-1,4,5,6-tetrahydro-1,3,5-triazin-2-yl]-2-propanesulfonamide |
14 | 5175489 | 321.8 | N-(1H-benzimidazol-2-ylmethyl)-4-chlorobenzenesulfonamide |
15 | 7841794 | 229.3 | 2-(1-azepanylmethyl)-1H-benzimidazole |
16 | 7994850 | 293.3 | 8-[(2,6-dimethyl-4-morpholinyl)methyl]-3-methyl-3,7-dihydro-1H-purine-2,6-dione |
17 | 4010128 | 205.2 | 2-(2-aminoethyl)-2,3-dihydrophthalazine-1,4-dione |
18 | 9326315 | 265.4 | (1H-benzimidazol-2-ylmethyl)(2-phenylpropyl)amine |
19 | 7973191 | 425.5 | N-{3-[5-(3-fluorophenyl)-1-(methylsulfonyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl}ethanesulfonamide |
20 | 5175507 | 356.2 | N-(1H-benzimidazol-2-ylmethyl)-3,4-dichlorobenzenesulfonamide |
21 | 9320045 | 315.3 | N-{4-[(2-oxo-1-imidazolidinyl)carbonyl]phenyl}-2-thiophenecarboxamide |
22 | 9309428 | 309.3 | N-{4-[(2-oxo-1-imidazolidinyl)carbonyl]phenyl}benzamide |
23 | 9059590 | 374.8 | 5-chloro-N-cyclopropyl-2-[2-(4-morpholinyl)-2-oxoethoxy]benzenesulfonamide |
24 | 9134776 | 298.3 | 4-{[(4-hydroxyphenyl)amino]sulfonyl}-2-thiophenecarboxamide |
25 | 7356076 | 343.8 | 2-amino-N-(4-chloro-2,5-dimethoxyphenyl)-4-oxo-5,6-dihydro-4H-1,3-thiazine-6-carboxamide |
26 | 9127934 | 338.8 | N-(3-chloro-2-methylphenyl)-3-[(methylsulfonyl)amino]benzamide |
27 | 7400955 | 230.3 | 4-cinnamoyl-2-piperazinone |
28 | 9120911 | 304.4 | N-(2-methylphenyl)-3-[(methylsulfonyl)amino]benzamide |
29 | 7802614 | 363.4 | N-benzyl-3-({[(4-fluorophenyl)amino]carbonyl}amino)benzamide |
30 | 9287619 | 311.4 | 3-[(anilinocarbonyl)amino]-N-(tert-butyl)benzamide |
31 | 5360857 | 315.4 | N-[2-(1H-benzimidazol-2-yl)ethyl]-4-methylbenzenesulfonamide |
32 | 5175505 | 301.4 | N-(1H-benzimidazol-2-ylmethyl)-4-methylbenzenesulfonamide |
33 | 9154810 | 305.4 | 3-[(methylsulfonyl)amino]-N-(4-pyridinylmethyl)benzamide |
34 | 9003359 | 364.2 | 2-{[(6-bromo-1,3-benzodioxol-5-yl)methyl]thio}-3H-imidazo[4,5-b]pyridine |
35 | 7806202 | 339.3 | 1-[(2,3-dioxo-1,2,3,4-tetrahydro-6-quinoxalinyl)sulfonyl]proline |
36 | 9015042 | 307.4 | 5-ethyl-N-(3-hydroxyphenyl)-2-methoxybenzenesulfonamide |
37 | 9203703 | 310.4 | 3-({4-[(3-hydroxypropyl)amino]-2-quinazolinyl}amino)phenol |
38 | 5186975 | 618.7 | N,N'-[methylenebis(2-hydroxy-4,1-phenylene)]bis(2,2-diphenylacetamide) |
39 | 9272567 | 324.4 | N-[5-(tetrahydro-2-furanylmethyl)-1,4,5,6-tetrahydro-1,3,5-triazin-2-yl]benzenesulfonamide |
40 | 9224447 | 236.3 | N-[5-(3-hydroxypropyl)-1,4,5,6-tetrahydro-1,3,5-triazin-2-yl]methanesulfonamide |
41 | 9336135 | 339.3 | 2-methoxy-N-{4-[(2-oxo-1-imidazolidinyl)carbonyl]phenyl}benzamide |
42 | 6907387 | 258.3 | 5-(2,3-dimethyl-1H-indol-5-yl)-4-methyl-2,4-dihydro-3H-1,2,4-triazole-3-thione |
43 | 9134168 | 353.4 | 3-[(phenylsulfonyl)amino]-N-3-pyridinylbenzamide |
44 | 9143017 | 424.5 | 2-({3-[(methylsulfonyl)amino]benzoyl}amino)-N-(3-pyridinylmethyl)benzamide |
45 | 9107321 | 304.3 | 1-(4-hydroxyphenyl)-5-oxo-N-(tetrahydro-2-furanylmethyl)-3-pyrrolidinecarboxamide |
46 | 9157889 | 367.4 | 3-{[(4-methylphenyl)sulfonyl]amino}-N-3-pyridinylbenzamide |
Claims (11)
- 하기 화학식 1 내지 60으로 표시되는 화합물로 구성된 군으로부터 선택되는 화합물, 또는 이의 약제학적으로 허용가능한 염, 용매화물 또는 수화물:화학식 1화학식 2화학식 3화학식 4화학식 5화학식 6화학식 7화학식 8화학식 9화학식 10화학식 11화학식 12화학식 13화학식 14화학식 15화학식 16화학식 17화학식 18화학식 19화학식 20화학식 21화학식 22화학식 23화학식 24화학식 25화학식 26화학식 27화학식 28화학식 29화학식 30화학식 31화학식 32화학식 33화학식 34화학식 35화학식 36화학식 37화학식 38화학식 39화학식 40화학식 41화학식 42화학식 43화학식 44화학식 45화학식 46화학식 47화학식 48화학식 49화학식 50화학식 51화학식 52화학식 53화학식 54화학식 55화학식 56화학식 57화학식 58화학식 59화학식 60
- (a) 제 1항의 화합물, 또는 이의 약제학적으로 허용가능한 염, 용매화물 또는 수화물의 약제학적 유효량; 및 (b) 약제학적으로 허용가능한 담체를 포함하는 암, 당뇨병성 망막증, 당뇨병, 혈우병성 관절증, 아테롬성 동맥경화, 켈로이드, 상처 과립화, 혈관 접착, 자가면역질환, 재발협착증, 장관 접착, 캣 스크래치 질환, 궤양, 간경병증, 당뇨병성 신장병증, 악성 신경화증, 혈전성 미소혈관증, 기관이식거부, 신사구체병증, 신경퇴행성 질환 및 염증성 질환으로 구성된 군으로부터 선택된 STAT3 관련 질환의 예방 또는 치료용 약제학적 조성물:
- 제 2 항에 있어서, 상기 화합물은 선택적으로 STAT3(signal transducer and activator of transcription 3)의 활성을 억제하는 것을 특징으로 하는 조성물.
- 제 2 항에 있어서, 상기 조성물은 암세포의 전이를 억제하는 것을 특징으로 하는 조성물.
- 제 2 항에 있어서, 상기 STAT3 관련 질환은 위암, 대장암, 폐암, 유방암, 난소암, 간암, 기관지암, 비인두암, 후두암, 췌장암, 방광암, 결장암, 자궁경부암, 뇌암, 전립선암, 골암, 피부암, 갑상선암, 백혈병, 림프종, 부신피질암, 부갑상선암, 요관암, 신경교종, 식도암, 소장암, 교모세포종, 뇌종양 및 신장암으로 구성된 군으로부터 선택된 암인 것을 특징으로 하는 조성물.
- 제 2 항에 있어서, 상기 STAT3 관련 질환은 알로페시아 그레아타(alopecia greata), 강직성 척추염, 항인지질 증후군, 자가면역 아디슨 질환, 부신의 자가면역 질환, 자가면역 용혈성 빈혈, 자가면역 간염, 자가면역 난소염 및 고환염, 자가면역 혈소판 감소증, 베체트병, 수포성 유천포창, 심근병증, 복강 스프루우-피부염 (celiac sprue-dermatitis), 만성피로 면역이상 증후군, 만성염증성 탈수초 다발성 신경병증, 처그스트라우스 증후군(Churg-strauss syndrome), 반흥성 유천포창, 크레스트 증후군(CREST syndrome), 한냉 응집소 질환, 크론씨병, 원판성 낭창, 복태성 복합 한냉 글로불린혈증, 섬유근통-섬유근염, 사구체 신염, 그레이브스 질환, 귈레인 바레 증후군, 하시모토 갑상선염, 특발성 폐섬유화증, 특발성 혈소판 감소성 자반증, IgA 신경염, 연소자성 관절염, 편평태선, 홍반성 루프스, 메니어르병, 혼합성 연결조직질환, 다발성 경화증, 타입I 또는 면역-매개 당뇨병, 중증근무력증, 심상성 천포창, 악성빈혈, 결정성 다발동맥염, 바달연골염, 자가면역성 다선 증후군, 류마티스 다발성 근통, 다발성 근염과 피부근염, 일차성 무감마 글로불린혈증, 일차성 당증성 간경변, 건선, 건선성 관절염, 레이노 현상, 라이터 증후군, 류마티스 관절염, 사르코이드증, 공피증, 강직인간 증후군, 전신성 홍반성루프스, 홍반성루프스, 다가야스동맥염(Takayasu's arteritis), 일시적동맥염, 거대세포 동맥염(giant cell arteritis), 궤양성 대장염, 포도막염, 백반증 및 베게너 육아종증으로 구성된 군으로부터 선택되는 자가면역 질환인 것을 특징으로 하는 조성물.
- 제 2 항에 있어서, 상기 STAT3 관련 질환은 천식, 엔세필리티스(encephalitis), 염증성 장염, 류마티스 관절염, 만성 폐쇄성 폐질환, 알러지, 아토피성 피부염, 건선, 폐혈병성 쇼크증, 페섬유증, 미분화 척추관절증, 크론씨병, 췌장염, 피부염, 미분화 관절병증, 관절염, 사구체신염, 기관지염, 염증성 골용해, 및 바이러스 또는 박테리아 감염에 의한 만성염증으로 구성된 군으로부터 선택되는 염증성 질환인 것을 특징으로 하는 조성물.
- 제 1항의 화합물 또는 이의 염을 유효성분으로 포함하는 암, 당뇨병성 망막증, 당뇨병, 혈우병성 관절증, 아테롬성 동맥경화, 켈로이드, 상처 과립화, 혈관 접착, 자가면역질환, 재발협착증, 장관 접착, 캣 스크래치 질환, 궤양, 간경병증, 당뇨병성 신장병증, 악성 신경화증, 혈전성 미소혈관증, 기관이식거부, 신사구체병증, 신경퇴행성 질환 및 염증성 질환으로 구성된 군으로부터 선택된 STAT3 관련 질환의 예방 또는 개선용 식품 조성물.
- (a) 제 1항의 화합물, 또는 이의 약제학적으로 허용가능한 염, 용매화물 또는 수화물의 약제학적 유효량; 및 (b) 약제학적으로 허용가능한 담체를 개체에 투여하는 단계를 포함하는 암, 당뇨병성 망막증, 당뇨병, 혈우병성 관절증, 아테롬성 동맥경화, 켈로이드, 상처 과립화, 혈관 접착, 자가면역질환, 재발협착증, 장관 접착, 캣 스크래치 질환, 궤양, 간경병증, 당뇨병성 신장병증, 악성 신경화증, 혈전성 미소혈관증, 기관이식거부, 신사구체병증, 신경퇴행성 질환 및 염증성 질환으로 구성된 군으로부터 선택된 STAT3 관련 질환의 예방 또는 치료방법.
- 암, 당뇨병성 망막증, 당뇨병, 혈우병성 관절증, 아테롬성 동맥경화, 켈로이드, 상처 과립화, 혈관 접착, 자가면역질환, 재발협착증, 장관 접착, 캣 스크래치 질환, 궤양, 간경병증, 당뇨병성 신장병증, 악성 신경화증, 혈전성 미소혈관증, 기관이식거부, 신사구체병증, 신경퇴행성 질환 및 염증성 질환으로 구성된 군으로부터 선택된 STAT3 관련 질환 예방 또는 치료용 약학적 조성물로 사용하기 위한 제1항의 화합물, 또는 이의 약제학적으로 허용가능한 염, 용매화물 또는 수화물의 용도.
- 암, 당뇨병성 망막증, 당뇨병, 혈우병성 관절증, 아테롬성 동맥경화, 켈로이드, 상처 과립화, 혈관 접착, 자가면역질환, 재발협착증, 장관 접착, 캣 스크래치 질환, 궤양, 간경병증, 당뇨병성 신장병증, 악성 신경화증, 혈전성 미소혈관증, 기관이식거부, 신사구체병증, 신경퇴행성 질환 및 염증성 질환으로 구성된 군으로부터 선택된 STAT3 관련 질환 예방 또는 개선용 식품 조성물로 사용하기 위한 제1항의 화합물, 또는 이의 약제학적으로 허용가능한 염, 용매화물 또는 수화물의 용도.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2017/012151 WO2019088311A1 (ko) | 2017-10-31 | 2017-10-31 | Stat3 저해활성을 갖는 화합물 및 이의 용도 |
CN201780098094.2A CN111615509A (zh) | 2017-10-31 | 2017-10-31 | 具有信号转导与转录激活因子3抑制活性的化合物及其用途 |
US16/760,436 US20200354327A1 (en) | 2017-10-31 | 2017-10-31 | Compound having stat3 inhibitory activity and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2017/012151 WO2019088311A1 (ko) | 2017-10-31 | 2017-10-31 | Stat3 저해활성을 갖는 화합물 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019088311A1 true WO2019088311A1 (ko) | 2019-05-09 |
Family
ID=66332073
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/012151 WO2019088311A1 (ko) | 2017-10-31 | 2017-10-31 | Stat3 저해활성을 갖는 화합물 및 이의 용도 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20200354327A1 (ko) |
CN (1) | CN111615509A (ko) |
WO (1) | WO2019088311A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021155426A1 (en) * | 2020-02-04 | 2021-08-12 | TroBio Therapeutics Pty Ltd | Quinazoline compounds and the use thereof in the treatment of cancer |
CN115154455A (zh) * | 2022-07-07 | 2022-10-11 | 南方医科大学南方医院 | 那布卡辛用于制备预防酒精相关的结肠癌肝转移的药物的用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002048117A1 (en) * | 2000-12-11 | 2002-06-20 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
WO2010151797A2 (en) * | 2009-06-26 | 2010-12-29 | University Of Massachusetts | Compounds for modulating rna binding proteins and uses therefor |
WO2014036022A1 (en) * | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
US8772311B2 (en) * | 2003-06-02 | 2014-07-08 | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. | Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof |
KR20140120508A (ko) * | 2013-04-03 | 2014-10-14 | 서울대학교산학협력단 | Stat3 저해활성을 갖는 화합물 및 이의 용도 |
-
2017
- 2017-10-31 US US16/760,436 patent/US20200354327A1/en not_active Abandoned
- 2017-10-31 WO PCT/KR2017/012151 patent/WO2019088311A1/ko active Application Filing
- 2017-10-31 CN CN201780098094.2A patent/CN111615509A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002048117A1 (en) * | 2000-12-11 | 2002-06-20 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
US8772311B2 (en) * | 2003-06-02 | 2014-07-08 | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. | Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof |
WO2010151797A2 (en) * | 2009-06-26 | 2010-12-29 | University Of Massachusetts | Compounds for modulating rna binding proteins and uses therefor |
WO2014036022A1 (en) * | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
KR20140120508A (ko) * | 2013-04-03 | 2014-10-14 | 서울대학교산학협력단 | Stat3 저해활성을 갖는 화합물 및 이의 용도 |
Non-Patent Citations (44)
Title |
---|
DATABASE CHEMICAL ABSTRACT 16 November 1984 (1984-11-16), Database accession no. 54220-74-5 * |
DATABASE Chemical Abstract 16 November 1984 (1984-11-16), retrieved from STN Database accession no. 727373-52-6 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1025759-36-7 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 10261-67-3 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1030431-77-6 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1030503-77-5 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1032383-45-1 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1071526-25-4 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1210003-20-5 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1210637-80-1 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1225141-29-6 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1259078-51-7 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1360209-70-6 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1360243-31-7 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1360268-89-8 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1938095-50-1 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 1994258-77-3 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 306319-73-3 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 330997-82-5 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 331950-41-5 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 406189-46-6 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 40788-59-8 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 414897-01-1 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 469878-96-4 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 522660-82-8 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 613657-60-6 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 64988-35-8 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 701970-75-4 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 708242-81-3 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 728887-06-7 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 791127-02-1 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 832688-29-6 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 838873-58-8 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 838900-06-4 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 87365-18-2 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 873673-90-6 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 916031-43-1 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 919027-03-5 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 928940-98-1 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 928970-37-0 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 928972-77-4 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 932256-25-2 * |
DATABASE CHEMICAL ABSTRACT Database accession no. 932256-46-7 * |
SHI, B.: "Design, synthesis and in vitro and in vivo antitumor activities of novel bivalent beta-carbolines", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 22 October 2013 (2013-10-22) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021155426A1 (en) * | 2020-02-04 | 2021-08-12 | TroBio Therapeutics Pty Ltd | Quinazoline compounds and the use thereof in the treatment of cancer |
CN115154455A (zh) * | 2022-07-07 | 2022-10-11 | 南方医科大学南方医院 | 那布卡辛用于制备预防酒精相关的结肠癌肝转移的药物的用途 |
Also Published As
Publication number | Publication date |
---|---|
US20200354327A1 (en) | 2020-11-12 |
CN111615509A (zh) | 2020-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008536818A (ja) | 11−βヒドロキシステロイドデヒドロゲナーゼ阻害剤 | |
KR20070113288A (ko) | 피리미딘 화합물 및 사용 방법 | |
WO2021230600A1 (ko) | 대사항암제를 포함하는 항암용 조성물 | |
WO2019088311A1 (ko) | Stat3 저해활성을 갖는 화합물 및 이의 용도 | |
KR101947152B1 (ko) | 신규한 벤젠설폰아미드 유도체 및 이의 용도 | |
WO2015160192A1 (ko) | 티에노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 백혈병 치료 및 예방용 약학 조성물 | |
KR101674463B1 (ko) | Stat3 저해활성을 갖는 화합물 및 이의 용도 | |
WO2012128521A2 (ko) | 프로게린 발현 억제제를 유효성분으로 함유하는 노화 관련 질환 치료용 약학조성물 및 상기 프로게린 발현 억제제의 스크리닝 방법 | |
WO2016080796A2 (ko) | 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도 | |
WO2012064159A2 (ko) | 항암용 조성물 | |
WO2020040582A1 (ko) | 신규한 벤조파이란 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 약학적 조성물 | |
WO2011159124A2 (ko) | Interleukin-6 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 | |
CN111153846A (zh) | 吡咯类化合物、其制备方法和药物组合物与用途 | |
WO2021107657A1 (ko) | 신규한 퀴나졸린 리독스 유도체 및 bet 억제제로서의 용도 | |
WO2019231261A1 (ko) | 신규 바이페닐 유도체 화합물 및 이의 용도 | |
WO2020055129A1 (ko) | 베르베논 유도체를 포함하는 암 치료 또는 예방용 조성물 | |
WO2017188690A1 (ko) | 페닐아세트알데히드를 포함하는, 유방암 줄기세포 성장 억제용 조성물 | |
WO2016111523A2 (ko) | HNF4-α 길항제 및 이의 용도 | |
WO2019182322A1 (ko) | 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 | |
WO2022050803A1 (ko) | 신규 메틸설폰아미드 유도체 화합물의 암전이 억제용 조성물 | |
WO2022065825A1 (ko) | 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물 | |
EP3386988A1 (en) | Novel dihydropyranopyrimidinone derivatives, and use thereof | |
WO2019231262A1 (ko) | 신규 바이페닐 유도체 화합물 및 이의 용도 | |
WO2010150927A1 (en) | Pharmaceutical composition for prevention and treatment of cancer diseases comprising benzamide derivatives | |
WO2019216653A1 (ko) | 신규한 구조를 갖는 화합물, 이를 포함하는 착물, 항암용 약학 조성물 및 항암제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17931065 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17931065 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 28/01/2021) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17931065 Country of ref document: EP Kind code of ref document: A1 |